Chapter 22 Ophthalmology Ophthalmic Prostaglandins Description Ophthalmic prostaglandins (PGs) are topically applied for treating glaucoma. Prototype and Common Drugs Prototype: latanoprost (all are PGF2α) Others: travoprost, bimatoprost, unoprostone MOA (Mechanism of Action) Glaucoma is characterized by increased intraocular pressure (IOP) and can lead to blindness if not treated. Strategies to reduce IOP include reducing the production and secretion of aqueous humor and facilitating its drainage. Drainage occurs via two main pathways 80% to 90% via Schlemm’s canal (the trabecular network) 10% to 20% via the uveoscleral route (Figure 22-1) PGs bind prostaglandin F (FP) receptors that are located on the ciliary muscle and reduce IOP by increasing outflow of aqueous humor through the uveoscleral pathway. This is thought to be accomplished through the following mechanisms: Relaxation of the ciliary muscle Vasodilatation as a contributor to early effects Remodeling or shrinking of the ciliary muscle, resulting in increased space for outflow as a mechanism for long-term control of glaucoma Administering exogenous PG-F (specifically PGF2α) stimulates the FP receptor and increases aqueous outflow through the mechanisms just described. Figure 22-1 Pharmacokinetics These PGs are administered topically to the eye, and only a small amount reaches the systemic circulation. Indication Glaucoma Contraindications Previous cystoid macular edema is a contraindication and previous incisional surgery on the eye is a risk factor; ocular PGs should be used with caution in these patients because of the increased risk of cystoid macular edema. Side Effects Local irritation: Conjunctival hyperemia (redness), itching, foreign body sensation, tearing, and eye pain are side effects. Blurred vision may occur. Pigmentation of the iris: This occurs in patients with mixed-color irises (green-brown or blue-brown) and is a result of increased deposition of melanin. Pigmentation of the palpebral skin (eyelids) also occurs. Eyelash growth occurs with unoprostone only. Cystoid macular edema involves accumulation of fluid in the macular area of the retina. This is a well-recognized complication of cataract surgery. Punctate epithelial keratopathy involves loss of superficial epithelial cells and associated defects on the cornea. Important Notes Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Like this:Like Loading... Related Related posts: Drug Interactions Autonomic Pharmacology Herbal Medications Hematology Stay updated, free articles. Join our Telegram channel Join Tags: Applied Pharmacology Jun 1, 2016 | Posted by admin in PHARMACY | Comments Off on Ophthalmology Full access? Get Clinical Tree
Chapter 22 Ophthalmology Ophthalmic Prostaglandins Description Ophthalmic prostaglandins (PGs) are topically applied for treating glaucoma. Prototype and Common Drugs Prototype: latanoprost (all are PGF2α) Others: travoprost, bimatoprost, unoprostone MOA (Mechanism of Action) Glaucoma is characterized by increased intraocular pressure (IOP) and can lead to blindness if not treated. Strategies to reduce IOP include reducing the production and secretion of aqueous humor and facilitating its drainage. Drainage occurs via two main pathways 80% to 90% via Schlemm’s canal (the trabecular network) 10% to 20% via the uveoscleral route (Figure 22-1) PGs bind prostaglandin F (FP) receptors that are located on the ciliary muscle and reduce IOP by increasing outflow of aqueous humor through the uveoscleral pathway. This is thought to be accomplished through the following mechanisms: Relaxation of the ciliary muscle Vasodilatation as a contributor to early effects Remodeling or shrinking of the ciliary muscle, resulting in increased space for outflow as a mechanism for long-term control of glaucoma Administering exogenous PG-F (specifically PGF2α) stimulates the FP receptor and increases aqueous outflow through the mechanisms just described. Figure 22-1 Pharmacokinetics These PGs are administered topically to the eye, and only a small amount reaches the systemic circulation. Indication Glaucoma Contraindications Previous cystoid macular edema is a contraindication and previous incisional surgery on the eye is a risk factor; ocular PGs should be used with caution in these patients because of the increased risk of cystoid macular edema. Side Effects Local irritation: Conjunctival hyperemia (redness), itching, foreign body sensation, tearing, and eye pain are side effects. Blurred vision may occur. Pigmentation of the iris: This occurs in patients with mixed-color irises (green-brown or blue-brown) and is a result of increased deposition of melanin. Pigmentation of the palpebral skin (eyelids) also occurs. Eyelash growth occurs with unoprostone only. Cystoid macular edema involves accumulation of fluid in the macular area of the retina. This is a well-recognized complication of cataract surgery. Punctate epithelial keratopathy involves loss of superficial epithelial cells and associated defects on the cornea. Important Notes Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Like this:Like Loading... Related Related posts: Drug Interactions Autonomic Pharmacology Herbal Medications Hematology Stay updated, free articles. Join our Telegram channel Join Tags: Applied Pharmacology Jun 1, 2016 | Posted by admin in PHARMACY | Comments Off on Ophthalmology Full access? Get Clinical Tree